Session

Prostate cancer: Outcomes of active surveillance

Poster Session 75

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chairs:
     A.R. Azzouzi, Angers (FR)
     A. Finelli, Toronto (CA)
     T. Pickles, Vancouver (CA)
  • Aims and objectives of this session

    The session focuses on outcomes of active surveillance

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 949
Long-term quality of life outcomes after active surveillance or curative treatment for prostate cancer

By: Venderbos L.D.F.1, Aluwini S.A.2, Roobol M.J.1, Bokhorst L.P.1, Oomens E.H.G.M.3, Bangma C.H.1, Korfage I.J.4

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, 3Amphia Hospital, Dept. of Urology, Breda, The Netherlands, 4Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands

950
Comparative analysis of immediate vs delayed prostatectomy in prostate cancer patients eligible for active surveillance

By: Mallya A.1, Karthikeyan V.S.1, Sivaraman A.2, Sanchez-Salas R.2, Galiano M.2, Rozet F.2, Barret E.2, Cathelineau X.2

Institutes: 1Institute of Nephrourology, Dept. of Urology, Bangalore, India, 2Institut Mutualiste Montsouris, Dept. of Urology, Paris, France

951
Use of initial active surveillance among men with low-risk prostate cancer

By: Finelli A.1, Komisarenko M.2, Timilshina N.3, Ahmad A.2, Alibhai S.4, Zlotta A.5, Hamilton R.2, Kulkarni G.2, Fleshner N.2

Institutes: 1Princess Margeret Hospital, Dept. of Surgical Oncology, Toronto, Canada, 2Princess Margaret Cancer Centre, Dept. of Surgical Oncology, Toronto, Canada, 3University of Toronto, Dept. of Health Services, Toronto, Canada, 4Toronto General Hospital, Dept. of Internal Medicine, Toronto, Canada, 5Mount Sinai Hospital, Dept. of Surgical Oncology, Toronto, Canada

952
Active surveillance (AS) following transperineal template guided saturation biopsy (TPSB) demonstrates a low rate of progression and conversion to radical treatment, with age and PSA associated with upgrading, upstaging and treatment

By: Sarkar D., Parr N.J.

Institutes: Wirral University Teaching Hospital, Dept. of Urology, Wirral, United Kingdom

953
Reclassified in active surveillance for prostate cancer: Was it worthwhile taking the risk?

By: Hefermehl L., Lehmann K.

Institutes: Kantonsspital Baden, Dept. of Urology, Baden, Switzerland

954
Longitudinal assessment of general health related QoL in Japanese patients undergoing active surveillance (AS): From an interim analysis of PRIAS-JAPAN

By: Sugimoto M., Hirama H., Kakehi Y.

Institutes: Kagawa University, Dept. of Urology, Kagawa, Japan

955
Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared to standard 12-core systematic biopsies for selection of prostate cancer patients for active surveillance

By: Radtke J.P.1, Kuru T.H.2, Bonekamp D.3, Freitag M.3, Kesch C.1, Wolf M.3, Alt C.4, Hatiboglu G.1, Boxler S.5, Pahernik S.1, Roth W.6, Roethke M.C.3, Schlemmer H-P.3, Hohenfellner M.1, Hadaschik B.1

Institutes: 1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2University Hopital Cologne, Dept. of Urology, Cologne, Germany, 3German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, 4Heinrich-Heine University, Dept. of Radiology, Düsseldorf, Germany, 5University Hospital Berne, Dept. of Urology, Berne, Switzerland, 6Heidelberg University, Dept. of Pathology, Heidelberg, Germany

956
Stability of health-related quality of life of patients included in an active surveillance program for prostate cancer

By: De La Peña E.1, Guijarro A.1, Hernández V.1, Fernández E.2, De La Morena J.M.1, Pozo C.1, Llorente C.1

Institutes: 1Hospital Universitario Fundación Alcorcón, Dept. of Urology, Alcorcon, Spain, 2Hospital Universitario Fundación Alcorcón, Dept. of Research, Alcorcon, Spain

957
A single center comparison between protocol based (PRIAS) and non-protocol based (ERSPC) prostate cancer active surveillance cohorts

By: Kalalahti I., Vasarainen H., Rannikko A.

Institutes: Helsinki University Central Hospital and University of Helsinki, Dept. of Urology, Helsinki, Finland

958
Integrating large datasets for the Movember Global Action Plan on active surveillance for low risk prostate cancer

By: Hulsen T.1, Obbink H.1, Van Der Linden W.1, De Jonge C.2, Nieboer D.3, Bruinsma S.4, Roobol M.4, Bangma C.4

Institutes: 1Philips Research, Dept. of Professional Health Solutions & Services, Eindhoven, The Netherlands, 2Philips Research, Dept. of Data Science, Eindhoven, The Netherlands, 3Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, 4Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

959
HAROW - a prospective non-interventional study comparing treatment options in localized prostate cancer: Observation of “active surveillance” patients with a mean follow up of 47.6 months

By: Herden J.1, Schnell D.2, Weissbach L.2

Institutes: 1Universityhospital Cologne, Dept. of Urology, Cologne, Germany, 2Stiftung Männergesundheit, Fondation of Men´s Health, Berlin, Germany

Summary and context
 T. Pickles, Vancouver (CA)